Australian drug company Novogen (ASX: NRT) has appointed Dr James Garner as its new chief executive, it has been announced.
It comes almost five months after company founder Graham Kelly left the cancer drug research company suddenly, saying he was leaving to resume work in medical research outside of tumors.
Dr Garner, who will take up office on February 1, 2016, brings broad experience in drug development and commercialization acquired through his previous roles in the biotech and pharmaceutical industries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze